Cost-effectiveness analysis of lenvatinib treatment for patients with unresectable hepatocellular carcinoma (uHCC) compared with sorafenib in Japan

Journal of Gastroenterology ◽

10.1007/s00535-019-01554-0 ◽

2019 ◽

Vol 54 (6) ◽

pp. 558-570 ◽

Author(s):

Masahiro Kobayashi ◽

Masatoshi Kudo ◽

Namiki Izumi ◽

Shuichi Kaneko ◽

Mie Azuma ◽

...

Keyword(s):

Hepatocellular Carcinoma ◽

Cost Effectiveness ◽

Cost Effectiveness Analysis ◽

Effectiveness Analysis ◽

Unresectable Hepatocellular Carcinoma

Download Full-text

Atezolizumab and bevacizumab combination compared with sorafenib as the first‐line systemic treatment for patients with unresectable hepatocellular carcinoma: A cost‐effectiveness analysis in China and the United states

Liver International ◽

10.1111/liv.14795 ◽

2021 ◽

Vol 41 (5) ◽

pp. 1097-1104

Author(s):

Feng Wen ◽

Hanrui Zheng ◽

Pengfei Zhang ◽

Weiting Liao ◽

Kexun Zhou ◽

...

Keyword(s):

United States ◽

Hepatocellular Carcinoma ◽

Cost Effectiveness ◽

Systemic Treatment ◽

The United States ◽

Cost Effectiveness Analysis ◽

Effectiveness Analysis ◽

Unresectable Hepatocellular Carcinoma

Download Full-text

PCN77 COST EFFECTIVENESS ANALYSIS OF LENVATINIB FOR THE FIRST-LINE TREATMENT OF INDIVIDUALS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA

Value in Health ◽

10.1016/j.jval.2020.04.1579 ◽

2020 ◽

Vol 23 ◽

pp. S37

Author(s):

X. Li ◽

G. Wudong ◽

Y. Wang

Keyword(s):

Hepatocellular Carcinoma ◽

Cost Effectiveness ◽

Cost Effectiveness Analysis ◽

Line Treatment ◽

Effectiveness Analysis ◽

Unresectable Hepatocellular Carcinoma ◽

First Line Treatment

Download Full-text

Cost-effectiveness analysis of transcatheter arterial chemoembolization with or without sorafenib for the treatment of unresectable hepatocellular carcinoma

Hepatobiliary & Pancreatic Diseases International ◽

10.1016/s1499-3872(17)60009-2 ◽

2017 ◽

Vol 16 (5) ◽

pp. 493-498 ◽

Author(s):

Rong-Ce Zhao ◽

Jing Zhou ◽

Yong-Gang Wei ◽

Fei Liu ◽

Ke-Fei Chen ◽

...

Keyword(s):

Hepatocellular Carcinoma ◽

Cost Effectiveness ◽

Transcatheter Arterial Chemoembolization ◽

Cost Effectiveness Analysis ◽

Effectiveness Analysis ◽

Unresectable Hepatocellular Carcinoma ◽

Arterial Chemoembolization

Download Full-text

Comparison of Drug-Eluting Embolics versus Conventional Transarterial Chemoembolization for the Treatment of Patients with Unresectable Hepatocellular Carcinoma: A Cost-Effectiveness Analysis

Journal of Vascular and Interventional Radiology ◽

10.1016/j.jvir.2020.09.022 ◽

2021 ◽

Vol 32 (1) ◽

pp. 2-12.e1 ◽

Author(s):

Xiao Wu ◽

Julius Chapiro ◽

Ajay Malhotra ◽

Nishita Kothary

Keyword(s):

Hepatocellular Carcinoma ◽

Cost Effectiveness ◽

Transarterial Chemoembolization ◽

Cost Effectiveness Analysis ◽

Effectiveness Analysis ◽

Unresectable Hepatocellular Carcinoma ◽

Download Full-text

Atezolizumab plus bevacizumab versus sorafenib as first‐line treatment for unresectable hepatocellular carcinoma: a cost‐effectiveness analysis

Cancer Communications ◽

10.1002/cac2.12110 ◽

2020 ◽

Vol 40 (12) ◽

pp. 743-745

Author(s):

Yanli Hou ◽

Bin Wu

Keyword(s):

Hepatocellular Carcinoma ◽

Cost Effectiveness ◽

Cost Effectiveness Analysis ◽

Line Treatment ◽

Effectiveness Analysis ◽

Unresectable Hepatocellular Carcinoma ◽

First Line Treatment

Download Full-text

PCN188 - ASSESSING THE ROBUSTNESS OF A COST-EFFECTIVENESS ANALYSIS OF LENVATINIB VERSUS SORAFENIB IN UNRESECTABLE HEPATOCELLULAR CARCINOMA IN JAPAN

Value in Health ◽

10.1016/j.jval.2018.09.270 ◽

2018 ◽

Vol 21 ◽

pp. S46

Author(s):

S. Ikeda ◽

M. Kudo ◽

N. Izumi ◽

S. Kaneko ◽

M. Kobayashi ◽

...

Keyword(s):

Hepatocellular Carcinoma ◽

Cost Effectiveness ◽

Cost Effectiveness Analysis ◽

Effectiveness Analysis ◽

Unresectable Hepatocellular Carcinoma

Download Full-text

P-2 First-line atezolizumab plus bevacizumab versus sorafenib in hepatocellular carcinoma: A cost-effectiveness analysis

Annals of Oncology ◽

10.1016/j.annonc.2021.05.057 ◽

2021 ◽

Vol 32 ◽

pp. S97

Author(s):

S. Chan ◽

C. Chiang ◽

S. Lee ◽

H. Choi

Keyword(s):

Hepatocellular Carcinoma ◽

Cost Effectiveness ◽

Cost Effectiveness Analysis ◽

Effectiveness Analysis

Download Full-text

Real-World Data for the Evaluation of Transarterial Radioembolization versus Sorafenib in Hepatocellular Carcinoma: A Cost-Effectiveness Analysis

Value in Health ◽

10.1016/j.jval.2016.09.2397 ◽

2017 ◽

Vol 20 (3) ◽

pp. 336-344 ◽

Author(s):

Carla Rognoni ◽

Oriana Ciani ◽

Silvia Sommariva ◽

Rosanna Tarricone

Keyword(s):

Hepatocellular Carcinoma ◽

Cost Effectiveness ◽

Cost Effectiveness Analysis ◽

Real World Data ◽

Transarterial Radioembolization ◽

Effectiveness Analysis

Download Full-text

Regorafenib treatment for patients with hepatocellular carcinoma who progressed on sorafenib—A cost-effectiveness analysis

PLoS ONE ◽

10.1371/journal.pone.0207132 ◽

2018 ◽

Vol 13 (11) ◽

pp. e0207132 ◽

Author(s):

Amir Shlomai ◽

Moshe Leshno ◽

Daniel A. Goldstein

Keyword(s):

Hepatocellular Carcinoma ◽

Cost Effectiveness ◽

Cost Effectiveness Analysis ◽

Effectiveness Analysis

Download Full-text

PIH31 COST-EFFECTIVENESS ANALYSIS OF REGORAFENIB AS A SECOND-LINE THERAPY IN THE TREATMENT OF HEPATOCELLULAR CARCINOMA IN CHINA

Value in Health ◽

10.1016/j.jval.2019.04.831 ◽

2019 ◽

Vol 22 ◽

pp. S187-S188

Author(s):

D. Xiao ◽

S. Zhu ◽

W. Sun ◽

J. Xuan

Keyword(s):

Hepatocellular Carcinoma ◽

Cost Effectiveness ◽

Cost Effectiveness Analysis ◽

Second Line ◽

Second Line Therapy ◽

Effectiveness Analysis ◽

Download Full-text